Alembic Pharmaceuticals is currently trading at Rs. 533.40, up by 4.05 points or 0.77% from its previous closing of Rs. 529.35 on the BSE.
The scrip opened at Rs. 531.25 and has touched a high and low of Rs. 537.00 and Rs. 531.20 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 537.00 and Rs. 515.95 respectively. The current market cap of the company is Rs. 10123.30 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.98% and 12.05% respectively.
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Solifenacin Succinate Tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Vesicare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc. Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin Succinate Tablets, 5 mg and 10 mg have an estimated market size of $967 million for twelve months ending December 2018 according to IQVIA. The company now has a total of 94 ANDA approvals (82 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
